|
|
Post by lennymnkd on Mar 16, 2021 17:16:14 GMT -5
81,000 pharmaceutical sales representatives
Currently, there are approximately 81,000 pharmaceutical sales representatives in the United States pursuing some 830,000 pharmaceutical prescribers.
en.m.wikipedia.org › wiki › Pharma...
Seems to be a numbers game ! Is it too simplistic to think if we had the REPS things would be different ?
|
|
|
|
Post by letitride on Mar 16, 2021 19:07:57 GMT -5
Okay people ... get them while they're hot. When MNKD starts it's run ... Just know that I have 8k shares out to sell at $5 pps. Don't get excited and just know that I am cleaning out my account of old, high priced MNKD stock.  Isn't it strange that an accountant wants to sell shares cheap knowing full well that the run is going to happen? It's just that I did so well recently, that I need to get losses to balance out my tax situation. Imagine that ... an accountant saying to sell shares to create losses ... so as not to make too much $$$. Ha! www.youtube.com/watch?v=BWrCRPldVZkBut, that's mytakeonit BTW, 8k shares out of 1M shares ... leaves me with 1M shares. HUH I cant count to a million but I am still counting the shares I have now. Have not finished counting but when I do, hoping they will be worth $100 a share. So till then. Lets Go! |
|
|
|
Post by kenken on Mar 16, 2021 20:09:35 GMT -5
|
|
|
|
Post by Clement on Jun 30, 2021 9:11:14 GMT -5
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). After giving effect to the additional sale of notes pursuant to the exercise in full of the initial purchasers’ option, MannKind estimates that the total net proceeds from the offering were approximately $222.9 million, after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. The notes are general unsecured obligations of MannKind and will accrue interest at a rate of 2.50% per annum, payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. Before December 1, 2025, holders will have the right to convert their notes only upon the occurrence of certain events. From and after December 1, 2025, until the close of business on the business day immediately preceding the maturity date, holders will have the right to convert all or any portion of their notes at their election. Upon conversion, MannKind will pay or deliver, as the case may be, cash, shares of MannKind’s common stock or a combination of cash and shares of MannKind’s common stock, at its election. The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $5.21 per share of common stock. The initial conversion price represents a premium of approximately 30% over the last reported sale of $4.01 per share of MannKind’s common stock on March 1, 2021. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. . .. ... Three and a half months later: Does this conversion price have anything to do with the share price now? Edit: On March 16, MNKD closed at $3.87. |
|
|
|
Post by mnkdfann on Jun 30, 2021 9:42:18 GMT -5
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). After giving effect to the additional sale of notes pursuant to the exercise in full of the initial purchasers’ option, MannKind estimates that the total net proceeds from the offering were approximately $222.9 million, after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. The notes are general unsecured obligations of MannKind and will accrue interest at a rate of 2.50% per annum, payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. Before December 1, 2025, holders will have the right to convert their notes only upon the occurrence of certain events. From and after December 1, 2025, until the close of business on the business day immediately preceding the maturity date, holders will have the right to convert all or any portion of their notes at their election. Upon conversion, MannKind will pay or deliver, as the case may be, cash, shares of MannKind’s common stock or a combination of cash and shares of MannKind’s common stock, at its election. The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $5.21 per share of common stock. The initial conversion price represents a premium of approximately 30% over the last reported sale of $4.01 per share of MannKind’s common stock on March 1, 2021. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. . .. ... Three and a half months later: Does this conversion price have anything to do with the share price now? I'll go out on a limb and guess that without more information, none of us can really know. If I understand the deal correctly, I'll say that if note holders had been converting notes for shares at $5.21, that could be a bullish or bearish sign, depending on their motivation for doing so. Really, it depends on the specifics. E.g. what 'events' are these:
holders will have the right to convert their notes only upon the occurrence of certain events
The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events
If you can direct me to a link to a detailed filing listing the specifics, I'll update my guess.  |
|
|
|
Post by mytakeonit on Jun 30, 2021 13:34:59 GMT -5
Or ... you can also note that analyst have been mentioning MNKD, brokerage houses have been loading up shares, and we're not even close to October. I don't think $5.21 has any significance anymore.
But, that's mytakeonit
|
|
|
|
Post by jlaw277 on Jun 30, 2021 13:50:52 GMT -5
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") pursuant to the exercise in full of the initial purchasers’ option in connection with MannKind’s previously-announced private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). After giving effect to the additional sale of notes pursuant to the exercise in full of the initial purchasers’ option, MannKind estimates that the total net proceeds from the offering were approximately $222.9 million, after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. The notes are general unsecured obligations of MannKind and will accrue interest at a rate of 2.50% per annum, payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2021. The notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased. Before December 1, 2025, holders will have the right to convert their notes only upon the occurrence of certain events. From and after December 1, 2025, until the close of business on the business day immediately preceding the maturity date, holders will have the right to convert all or any portion of their notes at their election. Upon conversion, MannKind will pay or deliver, as the case may be, cash, shares of MannKind’s common stock or a combination of cash and shares of MannKind’s common stock, at its election. The initial conversion rate is 191.8281 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $5.21 per share of common stock. The initial conversion price represents a premium of approximately 30% over the last reported sale of $4.01 per share of MannKind’s common stock on March 1, 2021. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. . .. ... Three and a half months later: Does this conversion price have anything to do with the share price now? Edit: On March 16, MNKD closed at $3.87. It has most likely has something to do with it. The note buyers want to make sure to make money whether the stock is going down or up. Now that we are getting beyond the conversion price on the notes, they will start to peel off their short exposure in an orderly manner. Or they may have already started to lock in short gains due to substantive news like the acceptance of the application by the FDA or even the recent Medicare announcement. What is a convertible note and who invests in them?A convertible note is a debt instrument that is convertible into shares of the issuer or another entity. They offer investors the downside protection of a debt instrument and the upside potential of an equity investment, but in return typically offer lower interest rates than straight debt instruments. Some investors may use convertible bonds as a component of an arbitrage opportunity, for example purchasing a convertible bond while taking a short position in the underlying common stock. This can have the effect of putting downward pressure on an issuer’s stock price at the time of a convertible note offering, particularly if the issuer does not execute a call spread transaction or stock repurchase in connection with the offering. Most convertible bond investors are large institutional investors and hedge funds. What other transactions regularly associated with convertible note offerings (such as call spread transactions or stock repurchases)?Convertible note offerings can be conducted on a stand‐alone basis, but there are associated transactions that many issuers engage in when they execute a convertible note offering. Many issuers use some or most of the proceeds of a convertible note offering to repurchase shares of common stock. These repurchases can be effected in negotiated transactions, on the open market or through an accelerated share repurchase program with an investment bank. Many issuers also enter into derivative transactions with an investment bank, often referred to as a “call option overlay” or “call spread transaction” to increase the effective conversion premium and reduce the effective dilution of the convertible note offering. These transactions may also help mitigate the downward pressure on an issuer’s stock price immediately after a convertible note offering that may result from short sales by investors purchasing convertible notes in the offering. The underwriters of the convertible note offering are generally the counterparties in an accelerated share repurchase program or a “call option overlay” or “call spread transaction,” but issuers may choose to use different investment banks as counterparties. www.gibsondunn.com/wp-content/uploads/2018/01/CAP-Convertible-Notes-Overview.pdf |
|
|
|
Post by mnkdfann on Jun 30, 2021 14:04:11 GMT -5
Three and a half months later: Does this conversion price have anything to do with the share price now? Edit: On March 16, MNKD closed at $3.87. It has most likely has something to do with it. The note buyers want to make sure to make money whether the stock is going down or up. Now that we are getting beyond the conversion price on the notes, they will start to peel off their short exposure in an orderly manner. Or they may have already started to lock in short gains due to substantive news like the acceptance of the application by the FDA or even the recent Medicare announcement. But wouldn't they be better off holding the notes and collecting the interest payments, given they can take advantage of the conversion at $5.21 whenever they like? The way I see it, so long as the SP is above / moving above the conversion price, they are wise to put off conversion as long as they can. They gain nothing (that I can see) by converting early. However, like I said above, without knowing what the 'certain events' mentioned in the notes are, I think we can only really guess whether or not the notes have anything to do with recent SP movement. For instance, it may be they want to convert as one of the 'certain events' occurred / is about to occur, and the conversion price is soon to be adjusted upward. But I can see other possibilities, some bullish, some bearish. |
|
|
|
Post by Clement on Jun 30, 2021 15:18:44 GMT -5
Thanks, jlaw!
" Now that we are getting beyond the conversion price on the notes, they will start to peel off their short exposure in an orderly manner."
And, they can choose to hang on to the notes or go ahead and take short-term gains (or a combination of the two).
|
|
Isn't it strange that an accountant wants to sell shares cheap knowing full well that the run is going to happen? It's just that I did so well recently, that I need to get losses to balance out my tax situation. 
